453 results on '"Corash L"'
Search Results
2. P‐TS‐24 | Design of ReCePI, a Randomized, Double‐Blinded, Phase III Study to Evaluate the Efficacy and Safety of Pathogen Reduced RBCs in Complex Cardiac Surgery
3. Pathogen Inactivated Blood Components: Advancing from Theory to Practice
4. In vitro Function of Double-Dose Platelets Treated with the Pathogen Inactivation Helinx™ Technology
5. Inactivation of Viruses, Bacteria, Protozoa, and Leukocytes in Labile Blood Components by Using Nucleic Acid Targeted Methods
6. Platelet Density, Heterogeneity and Platelet Ageing
7. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen–UVA photochemical treatment
8. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease
9. Frequency of Respiratory Adverse Events (AE) Reported During Active Hemovigilance After Transfusion of INTERCEPTTM Platelet Components (PC): SP312
10. Transfusion Experience in Pediatric Patients Using Platelet Components (PC) Prepared with Pathogen Inactivation (INTERCEPT™): S37-020D
11. Assessment of hemostasis in platelet transfusion clinical trials with differential follow-up
12. THE FREQUENCY OF CENTRAL NERVOUS SYSTEM (CNS) BLEEDING IN PLATELET TRANSFUSION DEPENDENT PATIENTS BEFORE AND AFTER INTRODUCTION OF PATHOGEN INACTIVATED COMPONENTS: A 9 YEAR HEMOVIGILANCE SURVEY: 4C-S27–04
13. Pathogen inactivation of plasma components
14. COMPARATIVE EFFECTIVENESS OF PLASMA PREPARED WITH PATHOGEN INACTIVATION (INTERCEPT≤) AND QUARANTINE CONVENTIONAL PLASMA FOR SUPPORT OF LIVER TRANSPLANTATION: 4D-S17–04
15. Assessment of Hemostasis in Platelet Transfusion Clinical Trials with Differential Follow-Up: SP385
16. Influence on HLA Alloimmunisation Frequency in Hematology Patients Supported with INTERCEPT Pathogen Inactivated (PI) Platelet Components (PC): SP208
17. Monitoring photochemical pathogen inactivation treatment using amotosalen and ultraviolet-A light: evaluation of an indicator label
18. Platelet-derived IL-27 and sOx40L associated with acute transfusion reactions: T7-PO78
19. Frequency of Prophylactic Transfusion Failure: A Novel Outcome to Evaluate Platelet Components Stored More than 5 Days: S54-030D
20. Comprehensive Evaluation of a New Process for S-303 Pathogen-Inactivation of Red Blood Cells: S15-010C
21. INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function – an in vitro analysis
22. ACTIVE HEMOVIGILANCE OF PEDIATRIC PATIENTS SUPPORTED WITH PLASMA COMPONENTS PREPARED WITH PHOTOCHEMICAL TREATMENT (INTERCEPTTM): P-245
23. AN ACTIVE HEMOVIGILANCE PROGRAM TO CHARACTERIZE THE SAFETY PROFILE OF 16,631 PLATELET COMPONENTS PREPARED WITH INTERCEPT BLOOD SYSTEMTM TRANSFUSED IN ROUTINE CLINICAL PRACTICE: P-244
24. Safety of Transfusions in Pediatric Patients with Platelet Components Prepared with Photochemical Treatment (INTERCEPT Blood SystemTM): S43-020E
25. INTERCEPT PLASMA RETAINS COAGULATION FACTOR ACTIVITY WHEN PREPARED FROM DIFFERENT PLASMA SOURCES: P-400
26. EVALUATION OF IN VITRO QUALITY OF STORED RBC AFTER TREATMENT WITH THE S-303 TREATMENT PROCESS: P-381
27. AN ACTIVE HEMOVIGILANCE PROGRAM UTILIZING AN EDC SYSTEM TO ASSESS SAFETY OF 6359 PLASMA COMPONENT TRANSFUSIONS PREPARED WITH THE INTERCEPT BLOOD SYSTEM: P-354
28. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment
29. Conservation of HPA (HPA) Immunologic Identity After Photochemical Treatment of Platelet Concentrates with Amotosalen (S-59) and UVA Light: SP280
30. Evaluation of Bacterial Inactivation in Pre-storage Pooled, Leukoreduced, WB-Derived Platelet Concentrates Suspended in Plasma Prepared With Photochemical Treatment: SP263
31. Complement Factors H and I Are Conserved in Plasma After Pathogen Inactivation with Amotosalen and UVA Light: SP87
32. Safety of Platelet Components Prepared with Photochemical Treatment (INTERCEPT™) Transfused to Pediatric Oncology-Hematology Patients: S53–030J
33. Impact of Pathogen Inactivation (INTERCEPT Blood System®) on Platelet Utilization During Three Years of Routine Use: S44–030I
34. Safety of Platelet Components Prepared with Photochemical Treatment Transfused During a Chikungunya Virus Epidemic: S46–030I
35. COMPARATIVE STUDY OF FIBRIN SEALANT PREPARED FROM CONVENTIONAL AND INTERCEPT BLOOD SYSTEM PLASMA USING THE CRYOSEAL FS-SYSTEM: 5A-S22-6
36. STABILITY OF COAGULATION FACTORS IN PLASMA PREPARED WITH PHOTOCHEMICAL TREATMENT (INTERCEPT™) STORED FOR ONE YEAR: P-389
37. FRESH FROZEN PLASMA FOR MANAGEMENT OF HEMOSTASIS DURING MINOR AND MAJOR SURGICAL PROCEDURES ASSOCIATED WITH COAGULOPATHY: P-388
38. COAGULATION FACTOR ACTIVITY IN 180 ML AND 325 ML UNITS OF PHOTOCHEMICALLY TREATED PLASMA (INTERCEPT™ PLASMA) AFTER STORAGE FOR 12 MONTHS AT 18°C: P-387
39. IMPACT OF PHOTOCHEMICAL TREATMENT (INTERCEPT) ON PLATELET USE IN ROUTINE PRACTICE: P-378
40. A PROSPECTIVE OBSERVATIONAL COHORT SAFETY STUDY OF 5,106 PLATELET TRANSFUSIONS PREPARED WITH PHOTOCHEMICAL TREATMENT (INTERCEPT™): P-379
41. PHOTOCHEMICAL PATHOGEN INACTIVATION OF HIGH-DOSE APHERESIS PLATELET CONCENTRATES USING THE INTERCEPT BLOOD SYSTEM: P-376
42. A MODIFIED TREATMENT PROCESS FOR PREPARATION OF S-303 RBC FOR PATHOGEN INACTIVATION SUBSTANTIALLY REDUCES THE POTENTIAL FOR CROSS-REACTIVITY: P-238
43. RAPID IMPLEMENTATION OF PHOTOCHEMICAL PATHOGEN INACTIVATION (INTERCEPT) FOR PREPARATION OF PLATELET COMPONENTS DURING AN EPIDEMIC OF CHIKUNGUNYA VIRUS: 5PS-34-04
44. INTERCEPT Plasma: Further In Vitro Evidence Of Comparability To Conventional FFP: SP272
45. Comparison Of BactAlert® And INTERCEPT® In Preventing The Release Of PLT Units Containing Low Numbers Of Viable Bacteria: SP70
46. vWF Cleaving Protease Activity And Inhibitors In Patients With Thrombotic Thrombocytopenic Purpura (TTP) Treated With INTERCEPT FFP Vs. Conventional FFP: Results Of A Phase III Trial: S92-040G
47. Conservation Of Human Platelet Antigen (HPA) Immunologic Reactivity After Photochemical Treatment With Amotosalen (S-59) And UVA Light: S91-040G
48. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution
49. Intercept platelets and plasma do not result in neoantigenicity: results of seven Phase 3 clinical trials
50. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: euroSPRITE trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.